Matches in Wikidata for { <http://www.wikidata.org/entity/Q37672544> ?p ?o ?g. }
- Q37672544 description "article científic" @default.
- Q37672544 description "article scientifique" @default.
- Q37672544 description "articolo scientifico" @default.
- Q37672544 description "artigo científico" @default.
- Q37672544 description "artículu científicu espublizáu en 2013" @default.
- Q37672544 description "bilimsel makale" @default.
- Q37672544 description "scientific article published on 15 June 2013" @default.
- Q37672544 description "vedecký článok" @default.
- Q37672544 description "vetenskaplig artikel" @default.
- Q37672544 description "videnskabelig artikel" @default.
- Q37672544 description "vědecký článek" @default.
- Q37672544 description "wetenschappelijk artikel" @default.
- Q37672544 description "wissenschaftlicher Artikel" @default.
- Q37672544 description "наукова стаття, опублікована в червні 2013" @default.
- Q37672544 description "научни чланак" @default.
- Q37672544 description "مقالة علمية نشرت في 15 يونيو 2013" @default.
- Q37672544 name "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 name "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 name "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes" @default.
- Q37672544 type Item @default.
- Q37672544 label "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 label "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 label "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes" @default.
- Q37672544 prefLabel "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 prefLabel "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 prefLabel "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes" @default.
- Q37672544 P1433 Q37672544-74735871-8443-4FF8-8D59-51741C4C6D75 @default.
- Q37672544 P1476 Q37672544-971A165D-A6A3-49E5-8520-79AE3BC8DA7F @default.
- Q37672544 P2093 Q37672544-08BE4496-53D4-4A4B-AC20-9C8EF671ECBA @default.
- Q37672544 P2093 Q37672544-54695062-244F-403B-B5A4-D875B5C26F1C @default.
- Q37672544 P2093 Q37672544-56921786-DEB6-4571-AF88-5062BFC50858 @default.
- Q37672544 P2093 Q37672544-5948903C-0719-48E2-8C0A-CCC8A1EE5C4E @default.
- Q37672544 P2093 Q37672544-59DCC48D-90A7-4F88-9ADD-2DC8F199457C @default.
- Q37672544 P2093 Q37672544-63DDF046-093E-45E8-A333-FA96A3C571B1 @default.
- Q37672544 P2093 Q37672544-B257A8E2-D62D-4F0F-B580-6BFB2F6900F7 @default.
- Q37672544 P2093 Q37672544-C15B6B4F-431A-4ACD-A78D-7FEBD3AC9B71 @default.
- Q37672544 P2093 Q37672544-E8978CBA-954E-4DAD-91AE-EC3362070760 @default.
- Q37672544 P2860 Q37672544-111367EB-81E3-495D-B6DE-B227FC53C595 @default.
- Q37672544 P2860 Q37672544-12E08728-59AC-46E4-BA9A-B8B779644F07 @default.
- Q37672544 P2860 Q37672544-17C11DDE-6B9A-4AB7-AADF-8B076E47BD44 @default.
- Q37672544 P2860 Q37672544-2A6ABC17-88C1-426E-B6BC-D0A14830381C @default.
- Q37672544 P2860 Q37672544-2CD52BD0-DBD0-498D-A1CC-267CC484CFF9 @default.
- Q37672544 P2860 Q37672544-301F966D-FB16-4712-BE71-3550DCFCA478 @default.
- Q37672544 P2860 Q37672544-32383CB0-D365-4130-807F-27BE9F2AC9D1 @default.
- Q37672544 P2860 Q37672544-35AA4A1A-24A2-49F6-9C24-DDB0865BAACC @default.
- Q37672544 P2860 Q37672544-39014368-694C-482F-A426-235D083F717F @default.
- Q37672544 P2860 Q37672544-3AE31935-50A0-4575-9C4E-F806B24EAB2B @default.
- Q37672544 P2860 Q37672544-3B75760E-3E96-4280-BA38-553E05780950 @default.
- Q37672544 P2860 Q37672544-5D97B5F2-F1AF-4DC1-85B1-2918E1FF8ACB @default.
- Q37672544 P2860 Q37672544-6380AC36-8292-4A35-A557-CEEF7EE8F480 @default.
- Q37672544 P2860 Q37672544-85D26E59-EE07-41BA-A752-03685B67574B @default.
- Q37672544 P2860 Q37672544-887C425A-0022-41E7-835B-3572A3E3B26A @default.
- Q37672544 P2860 Q37672544-A0706284-BEE8-4598-BD4A-4FCEAA0BE25C @default.
- Q37672544 P2860 Q37672544-CA7B0EE6-816D-4D96-AAD1-A331F7B157C5 @default.
- Q37672544 P2860 Q37672544-FAC74B38-E3B6-4A73-BAC3-8DCC61FFB166 @default.
- Q37672544 P304 Q37672544-66380907-7AE8-40A7-9E7F-1704319942B7 @default.
- Q37672544 P31 Q37672544-2CF83F9E-2494-4D1D-8253-4AC20A1BF4B4 @default.
- Q37672544 P356 Q37672544-CD7A5917-6D64-4390-9DF9-67DE6B4355C7 @default.
- Q37672544 P433 Q37672544-818047A9-E6D6-4D64-94EF-D42846C766B7 @default.
- Q37672544 P478 Q37672544-C1542120-796F-406E-9C68-A254980645F7 @default.
- Q37672544 P50 Q37672544-3397D756-34B7-4929-A011-62C887254776 @default.
- Q37672544 P50 Q37672544-DC543805-CD10-4C79-A106-17DDB0CBDB01 @default.
- Q37672544 P50 Q37672544-E6E8E76C-D87B-4B07-A8A9-97DB78B9CD41 @default.
- Q37672544 P577 Q37672544-C7594992-F03B-40AE-B47F-9F93CF2B5FFD @default.
- Q37672544 P698 Q37672544-A22B156B-420A-4C65-A26F-C3C336CD30BF @default.
- Q37672544 P921 Q37672544-D3A91AAE-CF72-4A03-BE7F-EFDA8CFFE67E @default.
- Q37672544 P932 Q37672544-8FD8C390-B256-4ABF-B7DC-06B7B0E833F7 @default.
- Q37672544 P356 J.LEUKRES.2013.05.011 @default.
- Q37672544 P698 23773898 @default.
- Q37672544 P1433 Q15716445 @default.
- Q37672544 P1476 "Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." @default.
- Q37672544 P2093 "Amir T Fathi" @default.
- Q37672544 P2093 "Daniel J Deangelo" @default.
- Q37672544 P2093 "Eyal C Attar" @default.
- Q37672544 P2093 "James W Fraser" @default.
- Q37672544 P2093 "Julia Foster" @default.
- Q37672544 P2093 "Karen K Ballen" @default.
- Q37672544 P2093 "Philip C Amrein" @default.
- Q37672544 P2093 "Richard M Stone" @default.
- Q37672544 P2093 "Steven McAfee" @default.
- Q37672544 P2860 Q33372867 @default.
- Q37672544 P2860 Q33376783 @default.
- Q37672544 P2860 Q33386405 @default.
- Q37672544 P2860 Q33389111 @default.
- Q37672544 P2860 Q33392434 @default.
- Q37672544 P2860 Q33392683 @default.
- Q37672544 P2860 Q33919884 @default.
- Q37672544 P2860 Q34415832 @default.
- Q37672544 P2860 Q34488712 @default.
- Q37672544 P2860 Q36625210 @default.
- Q37672544 P2860 Q39510395 @default.
- Q37672544 P2860 Q40362293 @default.
- Q37672544 P2860 Q40543180 @default.
- Q37672544 P2860 Q42913764 @default.
- Q37672544 P2860 Q43757315 @default.
- Q37672544 P2860 Q44850006 @default.
- Q37672544 P2860 Q46721125 @default.
- Q37672544 P2860 Q58865927 @default.
- Q37672544 P304 "1016-1020" @default.
- Q37672544 P31 Q13442814 @default.